On
Terms for the Lex Asea distribution
The Board of Directors of
In order to adjust the number of outstanding shares prior to the Lex Asea distribution, OncoZenge has completed a division of shares where each share has been divided into nine shares of the same class of shares as before, a so-called share split 9:1. The number of shares in OncoZenge after the completed share split amounted to 5,400,000. In addition, OncoZenge has carried out an equalizing share issue of a total of 456,622 shares to adjust the number of shares to be distributed to
Listing on Nasdaq First North Growth Market
In
Terms for the Rights Issue
The Board of Directors of OncoZenge has today, with the support of the authorization from the Extraordinary General Meeting on
The record date for the right to participate in the Rights Issue is
If not all shares are subscribed for with support of subscription rights, the remaining shares, within the framework of the maximum amount of the Rights Issue, shall be allotted: firstly, to those who have subscribed for shares with support of subscription rights (regardless of whether they were shareholders on the record date or not) and who have applied for subscription of shares without support of subscription rights and in the event that allotment to these cannot be made in full, the allotment shall be made pro rata in relation to the number of subscription rights that each of those who has applied for subscription of shares without support of subscription rights has exercised to subscribe for shares; secondly, to others who have only applied for subscription of shares without support of subscription rights and in the event that allotment to these cannot be made in full, allotment shall be made pro rata in relation to the total number of shares that the subscriber has applied for subscription of; and thirdly to those who have undertaken to guarantee subscription of shares in the Rights Issue, in proportion to such guarantee undertakings. To the extent that allotment at any stage according to the above cannot be made pro rata, allotment shall be made by drawing lots.
Subscription and guarantee commitments
In connection with the Rights Issue, existing shareholders in OncoZenge, including Östersjöstiftelsen,
Prospectus
Complete terms and conditions for the Rights Issue as well as other information about OncoZenge and the listing on Nasdaq First North Growth Market will be stated in the prospectus that is expected to be published on February 8[th], 2021.
Change in share capital and number of shares and dilution
The Rights Issue entails, if fully subscribed, that the share capital will increase by approximately
Timetable for Lex Asea, the Rights Issue and the listing on Nasdaq First North Growth Market
The timetable is indicative until Nasdaq's conditional approval has been obtained, which is expected to take place no later than
February 3, 2021 Last trading day in
February 4, 2021 First trading day in
February 5, 2021 Record date for the Lex Asea distribution of OncoZenge shares
February 8, 2021 Estimated date for publication of prospectus
February 12, 2021 First day of trading on Nasdaq First North Growth Market
February 15, 2021 Last trading day in OncoZenge with the right to receive subscription rights
February 16, 2021 First trading day in OncoZenge without the right to receive subscription rights
February 17, 2021 Record date for participation in the Rights Issue
February 19 - March 5, 2021 Subscription period
February 19 - March 2, 2021 Trading in subscription rights
March 9, 2021 Estimated date for publication of the outcome of the Rights Issue
Advisors
About oral mucositis and BupiZenge[®]
Globally, around 5 million people suffer from Oral mucositis ("OM") after cancer treatment. OM is an inflammation of the mucous membranes in the mouth and throat, which results in painful ulcers. OM is considered the most debilitating side effect of radiation therapy and chemotherapy and commonly occurs. After radiation therapy in the head and neck region, 90 percent of patients develop OM, and of the patients who are treated with chemotherapy around 30 percent are affected. OM causes severe pain, difficulty to swallow and talk, and can lead to interruptions in cancer treatment as well as increased health care costs.
The technology behind BupiZenge[®] includes a lozenge with bupivacaine, a long-acting local anesthetic that is currently only available in injectable form for other indications. In a previous phase 2 study in cancer patients, BupiZenge[®] has demonstrated statistically significant pain relief in the oral cavity and throat, the pain level in the mouth was reduced by 50 percent compared to the current treatment. The next step for BupiZenge[®] is a pivotal clinical phase 3 study for the European market and additional markets. A phase 3 study is expected to be initiated during the beginning of 2022 and the objective is top-line results in 2023.
For additional information, please contact:
About this information
The information was submitted for publication, through the agency of the contact persons set out above, at
About
About OncoZenge, www.oncozenge.se
https://news.cision.com/moberg-pharma/r/announcement-of-terms-for-the-fully-guaranteed-rights-issue-in-oncozenge--timetable-for-the-listing-,c3275553
https://mb.cision.com/Main/1662/3275553/1364789.pdf
(c) 2021 Cision. All rights reserved., source